 "Lupin launches generic Diovan tablets in US")
Lupin Pharmaceuticals Inc, the US-based subsidiary of the company, has launched its Valsartan tablets in strengths of 40 mg, 80 mg, 160 mg and 320 mg in the US market after getting nod from the US Food and Drug Administration (USFDA), Lupin Ltd said in a statement.
The Mumbai-based firm's product, which is is indicated for the treatment of hypertension, is the generic version of Novartis Pharmaceuticals Corporation's Diovan tablets, it added.
Also Read
According to IMS MAT September, 2014 ales data, Diovan tablets had annual US sales of $2.08 billion.
"This is Lupin's fourth abbreviated new drug application (ANDA) approvals in three weeks. These approvals and the subsequent launches represent a collective market size of over $5 billion for Lupin," the company said.
Lupin shares were trading at Rs 1,398 on the BSE, down 2.22% from its previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%